Engineering anti-cancer nanovaccine based on antigen cross-presentation. Issue 10 (18th October 2019)

• Record Type: Journal Article
• Authors: Warrier, Vaishnavi U.; Makandar, Amina I.; Garg, Manoj; Sethi, Gautam; Kant, Ravi; Pal, Jayanta K.; Yuba, Eiji; Gupta, Rajesh Kumar
• Is Part Of: Bioscience reports. Volume 39:Issue 10(2019)
• Publication Date: 2019-10-18
• Subjects: Antigen Cross-presentation -- Cancer immunotherapy -- DC-SIGN -- Dendritic cell (DC) -- Glycan -- Nanocarriers; Molecular biology -- Periodicals; Cytology -- Periodicals; 572.8
• DOI: 10.1042/BSR20193220
• Languages: English
• ISSNs: 0144-8463

Abstract

Abstract: Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex (MHC) class I molecules, thereby activating CD8 + T cells, contributing to tumor elimination through a mechanism known as antigen cross-presentation. A variety of factors such as maturation state of DCs, co-stimulatory signals, T-cell microenvironment, antigen internalization routes and adjuvants regulate the process of DC-mediated antigen cross-presentation. Recently, the development of successful cancer immunotherapies may be attributed to the ability of DCs to cross-present tumor antigens. In this review article, we focus on the underlying mechanism of antigen cross-presentation and ways to improve antigen cross-presentation in different DC subsets. We have critically summarized the recent developments in the generation of novel nanovaccines for robust CD8 + T-cell response in cancer. In this context, we have reviewed nanocarriers that have been used for cancer immunotherapeutics based on antigen cross-presentation mechanism. Additionally, we have also expressed our views on the future applications of this mechanism in curing cancer.